Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
telmisartan + amlodipine + rosuvastatin (Yuhan)
- Development stage
- Phase 1
- Lead developer
- Yuhan
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
YHP1604 is a fixed-dose combination (FDC) product developed by Yuhan Corporation, comprising telmisartan, amlodipine, and rosuvastatin. It is designed for the concurrent treatment of hypertension and dyslipidemia, two major risk factors for cardiovascular disease. Telmisartan serves as an angiotensin II receptor blocker (ARB), amlodipine as a dihydropyridine calcium channel blocker (CCB), and rosuvastatin as a statin (HMG-CoA reductase inhibitor). This triple combination simplifies complex medication regimens for patients requiring multiple therapies, thereby improving adherence and clinical outcomes. The product is approved and marketed in South Korea under brand names such as Duowell Plus.
- Brand names
- Duowell PlusTrilone
- Other names
- YHP1604YHP-1604YHP 1604
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)LTCC (Voltage-gated calcium channel (L-type))AGTR1 (Angiotensin II Type-1 receptor)
Beyond the preview
Go deeper on telmisartan + amlodipine + rosuvastatin (Yuhan).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on telmisartan + amlodipine + rosuvastatin (Yuhan).